Accueil > Actualité
Actualite financiere : Actualite bourse

Pfizer: positive results for a growth hormone

(CercleFinance.com) - Pfizer and Opko have announced positive results for a Phase III study for Somatrogon, a long-acting human growth hormone to treat children with growth hormone deficiency.


The study showed non-inferiority of this candidate drug in a weekly dose in pre-pubertal children, compared with somatropin in a daily dose, in terms of the growth rate after 12 months of treatment, thus reaching its primary endpoint.

For the record, both groups concluded a somatrogon agreement in 2014, under which Opko is responsible for conducting the clinical program and Pfizer, the drug's registering and marketing.


Copyright (c) 2019 CercleFinance.com. All rights reserved.
 

societes

marches

tendances

 
Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.